Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability

Dacomitinib (DMB) is a second-generation irreversible tyrosine kinase inhibitor (TKI) that is claimed to overcome the disadvantages of the resistance reported for first-line epidermal growth factor receptor (EGFR) TKIs. Towards the end of 2018, the US Food and Drug Administration approved DMB in the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PLoS One
Hauptverfasser: Abdelhameed, Ali S., Kadi, Adnan A., Attwa, Mohamed W., AlRabiah, Haitham
Format: Artigo
Sprache:Inglês
Veröffentlicht: Public Library of Science 2019
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6448865/
https://ncbi.nlm.nih.gov/pubmed/30947315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0214598
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge